MA29700B1 - Vaccin - Google Patents

Vaccin

Info

Publication number
MA29700B1
MA29700B1 MA30653A MA30653A MA29700B1 MA 29700 B1 MA29700 B1 MA 29700B1 MA 30653 A MA30653 A MA 30653A MA 30653 A MA30653 A MA 30653A MA 29700 B1 MA29700 B1 MA 29700B1
Authority
MA
Morocco
Prior art keywords
type
rotavirus strain
immune response
response against
vaccine
Prior art date
Application number
MA30653A
Other languages
English (en)
Inventor
Brigitte Desiree Alberte Colau
Vos Beatrice Arsene Virginie De
Original Assignee
Glaxosmithkline Biolog Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0516944A external-priority patent/GB0516944D0/en
Priority claimed from GB0521164A external-priority patent/GB0521164D0/en
Priority claimed from GB0608962A external-priority patent/GB0608962D0/en
Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa
Publication of MA29700B1 publication Critical patent/MA29700B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/15—Reoviridae, e.g. calf diarrhea virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12311—Rotavirus, e.g. rotavirus A
    • C12N2720/12334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

L'invention concerne une méthode destinée à induire une réponse immunitaire contre une souche de rotavirus. Cette méthode consiste à administrer à un sujet une composition comprenant une souche de rotavirus atténuée de type GxPy, cette composition générant une réponse immunitaire contre une souche de rotavirus qui n'est ni de type Gx ni de type Py.
MA30653A 2005-08-17 2008-02-13 Vaccin MA29700B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0516944A GB0516944D0 (en) 2005-08-17 2005-08-17 Vaccine
GB0521164A GB0521164D0 (en) 2005-10-18 2005-10-18 Vaccine
GB0608962A GB0608962D0 (en) 2006-05-05 2006-05-05 Vaccine

Publications (1)

Publication Number Publication Date
MA29700B1 true MA29700B1 (fr) 2008-08-01

Family

ID=37757924

Family Applications (1)

Application Number Title Priority Date Filing Date
MA30653A MA29700B1 (fr) 2005-08-17 2008-02-13 Vaccin

Country Status (25)

Country Link
US (1) US20090028828A1 (fr)
EP (2) EP1915173A2 (fr)
JP (1) JP5519934B2 (fr)
KR (1) KR20080036648A (fr)
AR (1) AR054916A1 (fr)
AU (1) AU2006281566B2 (fr)
BR (1) BRPI0615203A2 (fr)
CA (1) CA2619751C (fr)
CR (1) CR9759A (fr)
CY (1) CY1116135T1 (fr)
DK (1) DK2233153T3 (fr)
EA (1) EA014328B1 (fr)
ES (1) ES2534637T3 (fr)
HR (1) HRP20150310T1 (fr)
IL (1) IL189289A0 (fr)
MA (1) MA29700B1 (fr)
MX (1) MX2008002270A (fr)
NO (1) NO20080754L (fr)
PE (1) PE20070235A1 (fr)
PL (1) PL2233153T3 (fr)
PT (1) PT2233153E (fr)
SG (1) SG163571A1 (fr)
SI (1) SI2233153T1 (fr)
TW (1) TW200740457A (fr)
WO (1) WO2007020078A2 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0107510D0 (en) 2001-03-26 2001-05-16 Univ Bristol New elongase gene and a process for the production of -9-polyunsaturated fatty acids
EP2197283B1 (fr) * 2007-09-25 2013-07-17 Aridis Pharmaceuticals Formulations pour la préservation de rotavirus
US9311112B2 (en) * 2009-03-16 2016-04-12 Apple Inc. Event recognition
CN103747800A (zh) * 2011-04-28 2014-04-23 国际医学基金会 液体疫苗制剂
CN110227152A (zh) * 2012-04-23 2019-09-13 巴拉特生物技术国际有限公司 轮状病毒疫苗组合物及其制备方法
EP3359651A1 (fr) 2015-10-05 2018-08-15 THE UNITED STATES OF AMERICA, represented by the S Souche de rotavirus humain g9p[6]et utilisation comme vaccin

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992008786A1 (fr) * 1990-11-16 1992-05-29 James N. Gamble Institute Of Medical Research Rotavirus humains, vaccins et procedes
SK287261B6 (sk) * 1999-08-17 2010-04-07 Smithkline Beecham Biologicals S.A. Oslabená ľudská rotavírusová populácia, spôsob jej výroby, vakcínový prostriedok s jej obsahom a jej použitie
MXPA06002459A (es) * 2003-09-02 2006-06-20 Glaxosmithkline Biolog Sa Vacuna.

Also Published As

Publication number Publication date
EA200800320A1 (ru) 2008-10-30
JP5519934B2 (ja) 2014-06-11
EA014328B1 (ru) 2010-10-29
PL2233153T3 (pl) 2015-06-30
SI2233153T1 (sl) 2015-05-29
NO20080754L (no) 2008-05-15
DK2233153T3 (da) 2015-04-27
TW200740457A (en) 2007-11-01
JP2009504701A (ja) 2009-02-05
WO2007020078A2 (fr) 2007-02-22
AU2006281566B2 (en) 2011-09-01
PE20070235A1 (es) 2007-04-04
MX2008002270A (es) 2008-03-27
ES2534637T3 (es) 2015-04-27
KR20080036648A (ko) 2008-04-28
US20090028828A1 (en) 2009-01-29
IL189289A0 (en) 2008-06-05
SG163571A1 (en) 2010-08-30
BRPI0615203A2 (pt) 2011-05-10
EP2233153B1 (fr) 2015-01-21
CA2619751A1 (fr) 2007-02-22
CR9759A (es) 2008-05-05
CY1116135T1 (el) 2017-02-08
PT2233153E (pt) 2015-04-20
WO2007020078A3 (fr) 2007-05-24
AR054916A1 (es) 2007-07-25
HRP20150310T1 (hr) 2015-06-19
EP1915173A2 (fr) 2008-04-30
AU2006281566A1 (en) 2007-02-22
CA2619751C (fr) 2016-07-05
EP2233153A1 (fr) 2010-09-29

Similar Documents

Publication Publication Date Title
MA29459B1 (fr) Vaccins
WO2019118902A3 (fr) Compositions et procédés pour inhiber l'épuisement des lymphocytes t
MA29569B1 (fr) Composition immunogene
UA92505C2 (ru) Композиции на основе антитела против cd3
WO2005016235A3 (fr) Utilisation combinee d'inhibiteurs de l'inosine monophosphate deshydrogenase (impdh) et d'agonistes du toll-like recepteur
MA30531B1 (fr) Anticorps anti-dll4 et leurs procedes d'utilisation
TW200806316A (en) Yeast-based vaccine for inducing an immune response
ATE426412T1 (de) Adjuvante influenza-vakzine
TW200602077A (en) Compositions as adjuvants to improve immune responses to vaccines and methods of use
ATE552276T1 (de) Modifizierter anti-cd52-antikörper
PT1268498E (pt) Fosfonatos cardioprotectores
MA32018B1 (fr) Vaccin
DE602005020608D1 (de) NEISSERIA MENINGITIDIS IgtB LOS ALS ADJUVANS
TW200726479A (en) Method of inducing neutralizing antibodies to human immunodeficiency virus
FR3064264B1 (fr) Composition a base de tetrafluoropropene
DE602006011859D1 (de) T-cd4+-epitope der latenzantigene typ i und ii des epstein-barr-virus, die bei der mehrzahl von individuen in der kaukasischen bevölkerung erkannt werden können, und anwendungen davon
CY1116135T1 (el) Εμβολιο ροταϊου που διεγειρει ετεροτυπικη εγκαρσια προστασια
SG162818A1 (en) Multivalent entrain-and-amplify immunotherapeutics for carcinoma
SI1758555T1 (sl) Tvorec oleogela, ki vsebuje triterpen, oleogel, ki vsebuje triterpen, in postopek za pripravo oleogela, ki vsebuje triterpen
PT1879612E (pt) Utilização de péptidos nativos e de seus derivados optimizados em vacinação
DE602005002749D1 (de) Kaffeemaschine
WO2019191586A3 (fr) Poliovirus inactivé par irradiation, compositions les comprenant, et procédés de préparation
TW200609559A (en) Contact lenses and methods for their design
SG147465A1 (en) Vaccine
WO2012071521A3 (fr) Adjuvant